$9.42
$-6.75 (-35.79%)
End-of-day quote: 01/25/2022
NasdaqGM:EYPT

EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.

If you are interested in EYPT stock information, you might also be interested in competitors like NasdaqGS:REGN.

With a P/E ratio of 0.00, the stock appears relatively cheap compared to its index ^SPX at the moment.

The market capitalization of EyePoint Pharmaceuticals is currently at $0.36 B. This places it among the low capitalized companies.

The book value reported in the balance sheet results in a P/B ratio of 2.93.

With one share of EyePoint Pharmaceuticals investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.

For the risk analysis, the high beta factor should be noted, which is currently at a value of 1.14. The price of the stock NasdaqGM:EYPT is therefore subject to relatively strong fluctuations in relation to the overall market.

38.45% of EYPT Stocks is owned by insiders.

Since not enough Wall Street analysts have published their estimates, we are unfortunately unable to provide a reliable price target for the EYPT stock.

NasdaqGM:EYPT has a 52 week range of $4.00 - $21.50 and is currently trading around $9.42.

The low short sale ratio indicated that the value might increase in the foreseeable future.

0
Underperform
1
2
3
4
5
6
7
8
9
10
1M 3M YTD 1Y 2Y 5Y 10Y 20Y
P/E Ratio
0.0
Market Cap
0.36B
LT Debt/Cap
0.02%
Price-to-book Ratio
2.93
Earnings
11/03/2022
Dividend
$0.00
Div Yld
0.00%
Dividend Growth
0 Years
Beta
1.14
Short Interest
2.97%
Forecast 1Y
0.00%
Analyst Price Target
$0.00
LTG 5Y
0.00%
52 week range
$4.00 - $21.50